SynthesisScientific reports2021
Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20
Synthesis in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 49 citations in OpenAlex.
- Why antibody isotype matters for immunotherapy.Antibody therapeutics · 2026Review
- Biosimilars: A Virtuous Cycle of Sustainability and Innovation.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Follicular Lymphoma: Novel Therapies and Strategies for Optimal Therapeutic Sequencing.Current oncology reports · 2026Review
- Epidemiological landscape and clinical heterogeneity of primary pancreatic lymphoma: a population-based study.Cancer causes & control : CCC · 2026Article
- CD20-directed antibody-drug conjugates in non-hodgkin lymphoma: translating preclinical promise into clinical reality.Journal of hematology & oncology · 2026Review
- CD20 negativity at the start of second-line therapy predicts a shorter overall survival in B-cell lymphomas.Blood neoplasia · 2026Article
- Expression profiling reveals coordinated dysregulation of autophagy-associated proteins in marginal zone lymphoma and therapeutic implications.Oncology letters · 2026Article
- Therapeutic biologics interference in serological and pre-transfusion testing.Frontiers in immunology · 2026Review
- Contemporary review of primary membranous nephropathy.Frontiers in immunology · 2026Review
- Rituximab-Conjugated DART Nanoformulation for CD20-Targeted Drug Delivery in Non-Hodgkin Lymphoma.International journal of nanomedicine · 2026Article
- Adverse event reporting patterns of rituximab and obinutuzumab in B-cell non-Hodgkin lymphoma: a FAERS pharmacovigilance study.Frontiers in immunology · 2026Article
- Diagnosing pulmonary MALT lymphoma: a case of unilateral cystic lesions.Future science OA · 2025Article
- Battlegrounds of treatment resistance: decoding the tumor microenvironment.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Design of a water-soluble CD20 antigen with computational epitope scaffolding.Protein science : a publication of the Protein Society · 2025Article
- Potassium/sodium cation carriers robustly upregulate CD20 antigen by targeting MYC, and synergize with anti- CD20 immunotherapies to eliminate malignant B cells.Haematologica · 2025Article
- Immunotherapy in chronic lymphocytic leukemia: advances and challenges.Experimental hematology & oncology · 2025Review
- Osteonecrosis of the Jaw Associated with Obinutuzumab in a Patient with Preceding Follicular Non-Hodgkin's Lymphoma.Journal of personalized medicine · 2025Article
- Safety assessment of obinutuzumab: Real-world adverse event analysis based on the FAERS and JADER databases from 2013 to 2025.PloS one · 2025Article
- Obinutuzumab-induced severe acute thrombocytopenia: a case report and literature review.Frontiers in immunology · 2025Review
- Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms.Journal of hematology & oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rituximab combined with chemotherapy is the first-line induction therapy of CD20 positive B-cell non-Hodgkin lymphomas (CD20
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.